Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Metformin / / Anca Pantea Stoian, Manfredi Rizzo, editor
| Metformin / / Anca Pantea Stoian, Manfredi Rizzo, editor |
| Pubbl/distr/stampa | London : , : IntechOpen, , 2020 |
| Descrizione fisica | 1 online resource (242 pages) |
| Disciplina | 615.3 |
| Soggetto topico | Metformin |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910688465503321 |
| London : , : IntechOpen, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Multidisciplinary Experiences in Renal Replacement Therapy / / edited by Ane C.F. Nunes
| Multidisciplinary Experiences in Renal Replacement Therapy / / edited by Ane C.F. Nunes |
| Pubbl/distr/stampa | London : , : IntechOpen, , 2022 |
| Descrizione fisica | 1 online resource (158 pages) : illustrations |
| Disciplina | 615.3 |
| Soggetto topico | Blood - Filtration |
| ISBN | 1-83962-663-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910586642403321 |
| London : , : IntechOpen, , 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Natural History . Volume VIII : Books 28-32 : Medical zoology / / edited by William Henry Samuel Jones
| Natural History . Volume VIII : Books 28-32 : Medical zoology / / edited by William Henry Samuel Jones |
| Pubbl/distr/stampa | Cambridge, MA : , : Harvard University Press, , 1963 |
| Descrizione fisica | 1 online resource (608 pages) |
| Disciplina | 615.3 |
| Soggetto topico | Herbals - Early works to 1800 |
| ISBN | 0-674-99460-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction - Natural History - Book XXVIII - Book XXIX - Book XXX - Book XXXI - Book XXXII - Additional Notes - Popular Medicine in Ancient Italy - List of Diseases Mentioned by Pliny - Index of Fishes. |
| Altri titoli varianti | Natural History, Volume VIII |
| Record Nr. | UNISA-996199043703316 |
| Cambridge, MA : , : Harvard University Press, , 1963 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Natural History . Volume VI : Books 20-23, Plant products as used in medicine / / edited by William Henry Samuel Jones
| Natural History . Volume VI : Books 20-23, Plant products as used in medicine / / edited by William Henry Samuel Jones |
| Pubbl/distr/stampa | Cambridge, MA : , : Harvard University Press, , 1951 |
| Descrizione fisica | 1 online resource (560 pages) |
| Disciplina | 615.3 |
| Soggetto topico | Herbals |
| ISBN | 0-674-99431-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Preface - Introduction - Natural History - Book XX - Book XXI - Book XXII - Book XXIII - Index. |
| Altri titoli varianti | Natural History, Volume VI |
| Record Nr. | UNISA-996199044203316 |
| Cambridge, MA : , : Harvard University Press, , 1951 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Natural products and human diseases : pharmacology, molecular targets, and therapeutic benefits / / edited by Amirhossein Sahebkar and Thozhukat Sathyapalan
| Natural products and human diseases : pharmacology, molecular targets, and therapeutic benefits / / edited by Amirhossein Sahebkar and Thozhukat Sathyapalan |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (545 pages) |
| Disciplina | 615.3 |
| Collana | Advances in Experimental Medicine and Biology |
| Soggetto topico |
Biochemical markers
Natural products Terapèutica |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-73234-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910520090203321 |
| Cham, Switzerland : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Novel therapeutic proteins [[electronic resource] ] : selected case studies / / edited by Klaus Dembowsky and Peter Stadler
| Novel therapeutic proteins [[electronic resource] ] : selected case studies / / edited by Klaus Dembowsky and Peter Stadler |
| Pubbl/distr/stampa | Weinheim ; ; New York, : Wiley-VCH, c2001 |
| Descrizione fisica | 1 online resource (388 p.) |
| Disciplina |
615.3
660.6 |
| Altri autori (Persone) |
StadlerPeter, Dr.
DembowskyKlaus |
| Soggetto topico |
Gene therapy
Recombinant proteins |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-281-76404-3
9786611764043 3-527-61302-1 3-527-61303-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Novel Therapeutic Proteins; Foreword; Preface; Contents; Introduction and Overview; 1 Medical Applications of Recombinant Proteins in Humans; 1.1 Introduction; 1.2 Presently Approved Biotech Products; 1.3 Biotechnology Products in Clinical Development; 1.4 Specific Diseases and Applications; 1.4.1 Myocardial Infarction and Stroke; 1.4.2 Heart Failure; 1.4.3 Fibrosis; 1.4.4 Osteoporosis; 1.4.5 Obesity, Insulin Resistance, and Non-Insulin Dependent (Type II) Diabetes; 1.4.6 Sepsis; 1.4.7 Immunoenhancement; 1.4.7.1 Tumor Therapy; 1.4.7.2 Vaccines; 1.4.8 Immune Deviation
1.4.9 Multiple Sclerosis (MS)1.4.10 Psoriasis; 1.4.11 Arthritis; 1.4.12 Inflammatory Bowel Disease; 1.4.13 Allergy and Asthma; 1.4.14 Replacement Therapies; 1.4.15 Viral Infections; 1.4.16 Reproductive Medicine .; 1.4.17 Other; 1.5 Conclusion; 1.6 References; Recombinant Hormones; 2 Clinical Applications of Recombinant Human Erythropoietin; 2.1 Structure of Human Erythropoietin; 2.2 General Principles; 2.3 Medical Applications of Recombinant Human EPO; 2.3.1 The Anemia of Chronic Renal Failure (CRF); 2.3.2 Acquired Immunodeficiency Syndrome (AIDS) 2.3.3 Chemotherapy Induced Anemia of Non-Hematologic Malignancies 2.3.4 The Perioperative Setting; 2.3.4.1 Recombinant Human EPO without Autologous Blood Donation; 2.3.4.2 Recombinant Human EPO as an Adjunct to Autologous Bood Donation; 2.3.5 The Anemia of Prematurity; 2.3.6 The Anemia of Hematologic Malignancies; 2.3.7 Myelodysplastic Syndromes and Other Hematologic Stem Cell Disorders; 2.3.8 Bone Marrow Transplantation (BMT); 2.3.9 The Hemoglobinopathies; 2.3.10 The Anemia of Chronic Inflammation; 2.4 Patient Response and Medical Economics 2.5 Pharmacokinetics : Dosage, Routes of Administration. and Effect Monitoring 2.6 Iron Supplementation during rhEPO Treatment; 2.7 Future Directions; 2.8 References; 3 Human Recombinant Growth Hormone; 3.1 Introduction; 3.2 Hypothalamic Regulation; 3.2.1 Somatostatin; 3.2.2 Growth Hormone Releasing Hormone; 3.2.3 Other Neurotransmitters; 3.3 Peripheral Regulation of GH; 3.4 Mechanisms of Action of GH; 3.4.1 GH Receptor; 3.4.2 Metabolic Effects; 3.4.3 Insulin Growth Factors (IGF); 3.4.3.1 Circulation of IGF; 3.4.3.2 Receptors of IGF; 3.4.3.3 Actions of IGF; 3.5 GH Effects on Growth 3.5.1 Dwarfism 3.5.2 Gigantism; 3.5.3 Acromegaly; 3.5.4 GH Deficiency in the Adult; 3.6 Production of GH; 3.6.1 Preparations Obtained by Extractions; 3.6.2 Genetic Engineering of GH; 3.6.2.1 Synthesis in Prokaryotic Cells; 3.6.2.2 Second Synthetic Procedure for GH Synthesis; 3.6.2.3 Third Synthetic Procedure for GH Synthesis; 3.6.2.4 Synthesis of hGH in Eukaryotic Cells; 3.7 Therapy with GH; 3.7.1 Use of rhGH in the Treatment of GH Defiency; 3.7.2 Use of rhGH in Chronic Renal Failure (CRF); 3.7.3 Use of rhGH in Turner's Syndrome; 3.7.4 Use of GH in Different Catabolic States and in AIDS 3.8 References |
| Record Nr. | UNINA-9910144561603321 |
| Weinheim ; ; New York, : Wiley-VCH, c2001 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Novel therapeutic proteins [[electronic resource] ] : selected case studies / / edited by Klaus Dembowsky and Peter Stadler
| Novel therapeutic proteins [[electronic resource] ] : selected case studies / / edited by Klaus Dembowsky and Peter Stadler |
| Pubbl/distr/stampa | Weinheim ; ; New York, : Wiley-VCH, c2001 |
| Descrizione fisica | 1 online resource (388 p.) |
| Disciplina |
615.3
660.6 |
| Altri autori (Persone) |
StadlerPeter, Dr.
DembowskyKlaus |
| Soggetto topico |
Gene therapy
Recombinant proteins |
| ISBN |
1-281-76404-3
9786611764043 3-527-61302-1 3-527-61303-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Novel Therapeutic Proteins; Foreword; Preface; Contents; Introduction and Overview; 1 Medical Applications of Recombinant Proteins in Humans; 1.1 Introduction; 1.2 Presently Approved Biotech Products; 1.3 Biotechnology Products in Clinical Development; 1.4 Specific Diseases and Applications; 1.4.1 Myocardial Infarction and Stroke; 1.4.2 Heart Failure; 1.4.3 Fibrosis; 1.4.4 Osteoporosis; 1.4.5 Obesity, Insulin Resistance, and Non-Insulin Dependent (Type II) Diabetes; 1.4.6 Sepsis; 1.4.7 Immunoenhancement; 1.4.7.1 Tumor Therapy; 1.4.7.2 Vaccines; 1.4.8 Immune Deviation
1.4.9 Multiple Sclerosis (MS)1.4.10 Psoriasis; 1.4.11 Arthritis; 1.4.12 Inflammatory Bowel Disease; 1.4.13 Allergy and Asthma; 1.4.14 Replacement Therapies; 1.4.15 Viral Infections; 1.4.16 Reproductive Medicine .; 1.4.17 Other; 1.5 Conclusion; 1.6 References; Recombinant Hormones; 2 Clinical Applications of Recombinant Human Erythropoietin; 2.1 Structure of Human Erythropoietin; 2.2 General Principles; 2.3 Medical Applications of Recombinant Human EPO; 2.3.1 The Anemia of Chronic Renal Failure (CRF); 2.3.2 Acquired Immunodeficiency Syndrome (AIDS) 2.3.3 Chemotherapy Induced Anemia of Non-Hematologic Malignancies 2.3.4 The Perioperative Setting; 2.3.4.1 Recombinant Human EPO without Autologous Blood Donation; 2.3.4.2 Recombinant Human EPO as an Adjunct to Autologous Bood Donation; 2.3.5 The Anemia of Prematurity; 2.3.6 The Anemia of Hematologic Malignancies; 2.3.7 Myelodysplastic Syndromes and Other Hematologic Stem Cell Disorders; 2.3.8 Bone Marrow Transplantation (BMT); 2.3.9 The Hemoglobinopathies; 2.3.10 The Anemia of Chronic Inflammation; 2.4 Patient Response and Medical Economics 2.5 Pharmacokinetics : Dosage, Routes of Administration. and Effect Monitoring 2.6 Iron Supplementation during rhEPO Treatment; 2.7 Future Directions; 2.8 References; 3 Human Recombinant Growth Hormone; 3.1 Introduction; 3.2 Hypothalamic Regulation; 3.2.1 Somatostatin; 3.2.2 Growth Hormone Releasing Hormone; 3.2.3 Other Neurotransmitters; 3.3 Peripheral Regulation of GH; 3.4 Mechanisms of Action of GH; 3.4.1 GH Receptor; 3.4.2 Metabolic Effects; 3.4.3 Insulin Growth Factors (IGF); 3.4.3.1 Circulation of IGF; 3.4.3.2 Receptors of IGF; 3.4.3.3 Actions of IGF; 3.5 GH Effects on Growth 3.5.1 Dwarfism 3.5.2 Gigantism; 3.5.3 Acromegaly; 3.5.4 GH Deficiency in the Adult; 3.6 Production of GH; 3.6.1 Preparations Obtained by Extractions; 3.6.2 Genetic Engineering of GH; 3.6.2.1 Synthesis in Prokaryotic Cells; 3.6.2.2 Second Synthetic Procedure for GH Synthesis; 3.6.2.3 Third Synthetic Procedure for GH Synthesis; 3.6.2.4 Synthesis of hGH in Eukaryotic Cells; 3.7 Therapy with GH; 3.7.1 Use of rhGH in the Treatment of GH Defiency; 3.7.2 Use of rhGH in Chronic Renal Failure (CRF); 3.7.3 Use of rhGH in Turner's Syndrome; 3.7.4 Use of GH in Different Catabolic States and in AIDS 3.8 References |
| Record Nr. | UNINA-9910677407303321 |
| Weinheim ; ; New York, : Wiley-VCH, c2001 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Novel therapeutic proteins [[electronic resource] ] : selected case studies / / edited by Klaus Dembowsky and Peter Stadler
| Novel therapeutic proteins [[electronic resource] ] : selected case studies / / edited by Klaus Dembowsky and Peter Stadler |
| Pubbl/distr/stampa | Weinheim ; ; New York, : Wiley-VCH, c2001 |
| Descrizione fisica | 1 online resource (388 p.) |
| Disciplina |
615.3
660.6 |
| Altri autori (Persone) |
StadlerPeter, Dr.
DembowskyKlaus |
| Soggetto topico |
Gene therapy
Recombinant proteins |
| ISBN |
1-281-76404-3
9786611764043 3-527-61302-1 3-527-61303-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Novel Therapeutic Proteins; Foreword; Preface; Contents; Introduction and Overview; 1 Medical Applications of Recombinant Proteins in Humans; 1.1 Introduction; 1.2 Presently Approved Biotech Products; 1.3 Biotechnology Products in Clinical Development; 1.4 Specific Diseases and Applications; 1.4.1 Myocardial Infarction and Stroke; 1.4.2 Heart Failure; 1.4.3 Fibrosis; 1.4.4 Osteoporosis; 1.4.5 Obesity, Insulin Resistance, and Non-Insulin Dependent (Type II) Diabetes; 1.4.6 Sepsis; 1.4.7 Immunoenhancement; 1.4.7.1 Tumor Therapy; 1.4.7.2 Vaccines; 1.4.8 Immune Deviation
1.4.9 Multiple Sclerosis (MS)1.4.10 Psoriasis; 1.4.11 Arthritis; 1.4.12 Inflammatory Bowel Disease; 1.4.13 Allergy and Asthma; 1.4.14 Replacement Therapies; 1.4.15 Viral Infections; 1.4.16 Reproductive Medicine .; 1.4.17 Other; 1.5 Conclusion; 1.6 References; Recombinant Hormones; 2 Clinical Applications of Recombinant Human Erythropoietin; 2.1 Structure of Human Erythropoietin; 2.2 General Principles; 2.3 Medical Applications of Recombinant Human EPO; 2.3.1 The Anemia of Chronic Renal Failure (CRF); 2.3.2 Acquired Immunodeficiency Syndrome (AIDS) 2.3.3 Chemotherapy Induced Anemia of Non-Hematologic Malignancies 2.3.4 The Perioperative Setting; 2.3.4.1 Recombinant Human EPO without Autologous Blood Donation; 2.3.4.2 Recombinant Human EPO as an Adjunct to Autologous Bood Donation; 2.3.5 The Anemia of Prematurity; 2.3.6 The Anemia of Hematologic Malignancies; 2.3.7 Myelodysplastic Syndromes and Other Hematologic Stem Cell Disorders; 2.3.8 Bone Marrow Transplantation (BMT); 2.3.9 The Hemoglobinopathies; 2.3.10 The Anemia of Chronic Inflammation; 2.4 Patient Response and Medical Economics 2.5 Pharmacokinetics : Dosage, Routes of Administration. and Effect Monitoring 2.6 Iron Supplementation during rhEPO Treatment; 2.7 Future Directions; 2.8 References; 3 Human Recombinant Growth Hormone; 3.1 Introduction; 3.2 Hypothalamic Regulation; 3.2.1 Somatostatin; 3.2.2 Growth Hormone Releasing Hormone; 3.2.3 Other Neurotransmitters; 3.3 Peripheral Regulation of GH; 3.4 Mechanisms of Action of GH; 3.4.1 GH Receptor; 3.4.2 Metabolic Effects; 3.4.3 Insulin Growth Factors (IGF); 3.4.3.1 Circulation of IGF; 3.4.3.2 Receptors of IGF; 3.4.3.3 Actions of IGF; 3.5 GH Effects on Growth 3.5.1 Dwarfism 3.5.2 Gigantism; 3.5.3 Acromegaly; 3.5.4 GH Deficiency in the Adult; 3.6 Production of GH; 3.6.1 Preparations Obtained by Extractions; 3.6.2 Genetic Engineering of GH; 3.6.2.1 Synthesis in Prokaryotic Cells; 3.6.2.2 Second Synthetic Procedure for GH Synthesis; 3.6.2.3 Third Synthetic Procedure for GH Synthesis; 3.6.2.4 Synthesis of hGH in Eukaryotic Cells; 3.7 Therapy with GH; 3.7.1 Use of rhGH in the Treatment of GH Defiency; 3.7.2 Use of rhGH in Chronic Renal Failure (CRF); 3.7.3 Use of rhGH in Turner's Syndrome; 3.7.4 Use of GH in Different Catabolic States and in AIDS 3.8 References |
| Record Nr. | UNINA-9910840957503321 |
| Weinheim ; ; New York, : Wiley-VCH, c2001 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Peptides as drugs [[electronic resource] ] : discovery and development / / edited by Bernd Groner
| Peptides as drugs [[electronic resource] ] : discovery and development / / edited by Bernd Groner |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, c2009 |
| Descrizione fisica | 1 online resource (244 p.) |
| Disciplina |
615.19
615.3 |
| Altri autori (Persone) | GronerB (Bernd) |
| Soggetto topico |
Drugs - Design
Peptide drugs |
| ISBN |
1-282-46085-4
9786612460852 3-527-62684-0 3-527-62683-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Peptides as Drugs; Contents; Preface; List of Contributors; 1: Peptides as Drugs: Discovery and Development; 1.1 Discovery of New Potential Drug Targets and the Limitations of Druggability; 1.2 Protein Interaction Domains Are at the Core of Signaling Pathways; 1.3 Peptides as Inhibitors of Protein Interactions; References; 2: Mimics of Growth Factors and Cytokines; 2.1 Introduction; 2.2 The Cytokines; 2.2.1 The Receptors; 2.2.2 "Simple" Receptors; 2.2.3 "Complex" Receptors; 2.3 Defining Receptor Recognition Sites in Cytokines Using Chimeric Proteins
2.4 Receptor Recognition Sites are Organized as Exchangeable Modules2.5 The Concept of Fusing the Cytokine to the Soluble Receptor: Hyper-IL-6; 2.6 Antagonists Specifically Inhibiting IL-6 Trans-Signaling; 2.7 In Vitro Evolution of Peptides and Proteins; 2.7.1 Platforms for the Selection of High-Affinity Binders; 2.7.2 Agonists and Antagonists of Cytokines and Growth Hormones; 2.8 Concluding Remarks; References; 3: Peptides Derived from Exon v6 of the CD44 Extracellular Domain Prevent Activation of Receptor Tyrosine Kinases and Subsequently Angiogenesis and Metastatic Spread of Tumor Cells 3.1 Introduction3.2 CD44 Proteins and Their Involvement in RTK Activation; 3.3 CD44v6 Acts as a Coreceptor for c-Met and Ron; 3.4 Three Amino Acids in CD44 Exon v6 Are Crucial for the CD44v6 Coreceptor Function, and Small Peptides Can Interfere with This Function; 3.5 The Ectodomain of CD44v6 Binds to HGF; 3.6 Peptides Corresponding to Exon v6 of CD44 Inhibit Metastatic Spread of Tumor Cells; 3.7 The Significance of the Collaboration between CD44v6 and c-Met In Vivo; 3.8 The CD44v6 Peptides Interfere with Angiogenesis; 3.9 Outlook; References 4: Peptide Aptamers Targeting the Viral E6 Oncoprotein Induce Apoptosis in HPV-positive Cancer Cells4.1 Human Papillomaviruses and Oncogenesis; 4.1.1 Cervical Cancer; 4.1.2 The E6 and E7 Genes; 4.2 Peptide Aptamers Targeting the HPV E6 Oncoprotein; 4.3 E6-Targeting Peptide Aptamers: Therapeutic Perspectives; 4.3.1 Therapeutic Target Protein Evaluation by Peptide Aptamers; 4.3.2 The Intrinsic Therapeutic Potential of Peptide Aptamers; 4.3.3 Identification of Functional Peptide Mimics by Displacement Screening; 4.4 Perspectives; References 5: The Prevention of HIV Infection with Viral Entry Inhibitors5.1 Introduction: The Potential of Peptides as Drugs in the Treatment of HIV Infection; 5.2 The HIV Entry Process; 5.3 Peptides that Inhibit Receptor or Coreceptor Binding; 5.3.1 Physiological Antimicrobial Peptides; 5.3.1.1 Defensins; 5.3.2 Chemokines; 5.3.3 Synthetic Peptides and Peptidomimetics; 5.4 Inhibitors of the Viral and Cellular Membrane Fusion Process; 5.5 Entry Inhibitory Peptides Selected by the Phage Display Technology; 5.6 Limitations of Peptides in the Treatment of HIV Infection 5.7 Strategies to Prolong the In Vivo Half-Life of Antiviral Peptides |
| Record Nr. | UNINA-9910139946403321 |
| Weinheim, : Wiley-VCH, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Peptides as drugs [[electronic resource] ] : discovery and development / / edited by Bernd Groner
| Peptides as drugs [[electronic resource] ] : discovery and development / / edited by Bernd Groner |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, c2009 |
| Descrizione fisica | 1 online resource (244 p.) |
| Disciplina |
615.19
615.3 |
| Altri autori (Persone) | GronerB (Bernd) |
| Soggetto topico |
Drugs - Design
Peptide drugs |
| ISBN |
1-282-46085-4
9786612460852 3-527-62684-0 3-527-62683-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Peptides as Drugs; Contents; Preface; List of Contributors; 1: Peptides as Drugs: Discovery and Development; 1.1 Discovery of New Potential Drug Targets and the Limitations of Druggability; 1.2 Protein Interaction Domains Are at the Core of Signaling Pathways; 1.3 Peptides as Inhibitors of Protein Interactions; References; 2: Mimics of Growth Factors and Cytokines; 2.1 Introduction; 2.2 The Cytokines; 2.2.1 The Receptors; 2.2.2 "Simple" Receptors; 2.2.3 "Complex" Receptors; 2.3 Defining Receptor Recognition Sites in Cytokines Using Chimeric Proteins
2.4 Receptor Recognition Sites are Organized as Exchangeable Modules2.5 The Concept of Fusing the Cytokine to the Soluble Receptor: Hyper-IL-6; 2.6 Antagonists Specifically Inhibiting IL-6 Trans-Signaling; 2.7 In Vitro Evolution of Peptides and Proteins; 2.7.1 Platforms for the Selection of High-Affinity Binders; 2.7.2 Agonists and Antagonists of Cytokines and Growth Hormones; 2.8 Concluding Remarks; References; 3: Peptides Derived from Exon v6 of the CD44 Extracellular Domain Prevent Activation of Receptor Tyrosine Kinases and Subsequently Angiogenesis and Metastatic Spread of Tumor Cells 3.1 Introduction3.2 CD44 Proteins and Their Involvement in RTK Activation; 3.3 CD44v6 Acts as a Coreceptor for c-Met and Ron; 3.4 Three Amino Acids in CD44 Exon v6 Are Crucial for the CD44v6 Coreceptor Function, and Small Peptides Can Interfere with This Function; 3.5 The Ectodomain of CD44v6 Binds to HGF; 3.6 Peptides Corresponding to Exon v6 of CD44 Inhibit Metastatic Spread of Tumor Cells; 3.7 The Significance of the Collaboration between CD44v6 and c-Met In Vivo; 3.8 The CD44v6 Peptides Interfere with Angiogenesis; 3.9 Outlook; References 4: Peptide Aptamers Targeting the Viral E6 Oncoprotein Induce Apoptosis in HPV-positive Cancer Cells4.1 Human Papillomaviruses and Oncogenesis; 4.1.1 Cervical Cancer; 4.1.2 The E6 and E7 Genes; 4.2 Peptide Aptamers Targeting the HPV E6 Oncoprotein; 4.3 E6-Targeting Peptide Aptamers: Therapeutic Perspectives; 4.3.1 Therapeutic Target Protein Evaluation by Peptide Aptamers; 4.3.2 The Intrinsic Therapeutic Potential of Peptide Aptamers; 4.3.3 Identification of Functional Peptide Mimics by Displacement Screening; 4.4 Perspectives; References 5: The Prevention of HIV Infection with Viral Entry Inhibitors5.1 Introduction: The Potential of Peptides as Drugs in the Treatment of HIV Infection; 5.2 The HIV Entry Process; 5.3 Peptides that Inhibit Receptor or Coreceptor Binding; 5.3.1 Physiological Antimicrobial Peptides; 5.3.1.1 Defensins; 5.3.2 Chemokines; 5.3.3 Synthetic Peptides and Peptidomimetics; 5.4 Inhibitors of the Viral and Cellular Membrane Fusion Process; 5.5 Entry Inhibitory Peptides Selected by the Phage Display Technology; 5.6 Limitations of Peptides in the Treatment of HIV Infection 5.7 Strategies to Prolong the In Vivo Half-Life of Antiviral Peptides |
| Record Nr. | UNINA-9910830943903321 |
| Weinheim, : Wiley-VCH, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
